MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Keros Therapeutics Long Term Debt Current 2011-2026 | KROS
Annual Long Term Debt Current Keros Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.98 M | 1 M | 455 K | 862 K | 423 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.98 M | 423 K | 945 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Apellis Pharmaceuticals
APLS
|
7.09 M | $ 20.7 | -1.24 % | $ 2.61 B |  USA |
 |
Aptorum Group Limited
APM
|
433 K | $ 0.84 | 7.59 % | $ 4.58 M | China |
 |
Axsome Therapeutics
AXSM
|
434 K | $ 166.38 | 1.52 % | $ 8.28 B | USA |
 |
AbCellera Biologics
ABCL
|
5.82 M | $ 3.82 | 5.82 % | $ 1.14 B |  Canada |
 |
Capricor Therapeutics
CAPR
|
749 K | $ 26.86 | -3.83 % | $ 719 M | USA |
 |
Codexis
CDXS
|
2.83 M | $ 1.02 | 0.99 % | $ 74.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Cellectis S.A.
CLLS
|
8.38 M | $ 3.8 | -2.06 % | $ 116 M |  France |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Collegium Pharmaceutical
COLL
|
1.41 M | $ 41.6 | -0.17 % | $ 1.32 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
1.08 M | $ 35.97 | 0.76 % | $ 3.74 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
437 K | $ 23.88 | 3.47 % | $ 2.92 B | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.44 M | $ 8.35 | -2.57 % | $ 36.1 M | USA |
 |
Curis
CRIS
|
1.34 M | $ 1.08 | -5.26 % | $ 6.81 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
6.49 M | $ 40.68 | -1.02 % | $ 3.83 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
1.37 M | $ 17.89 | -2.03 % | $ 859 M | USA |
 |
Champions Oncology
CSBR
|
1.47 M | $ 6.07 | 2.71 % | $ 82.9 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
242 K | $ 0.72 | -2.3 % | $ 4.84 M | USA |
 |
CEL-SCI Corporation
CVM
|
227 K | $ 3.83 | -10.09 % | $ 244 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
Daré Bioscience
DARE
|
549 K | $ 1.61 | -5.29 % | $ 13.7 M | USA |
 |
DBV Technologies S.A.
DBVT
|
654 K | $ 23.25 | 10.77 % | $ 2.26 B | France |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Precision BioSciences
DTIL
|
1.13 M | $ 4.33 | 3.1 % | $ 16.6 M | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
2.59 M | $ 3.34 | 0.3 % | $ 1.2 M | USA |
 |
Dyadic International
DYAI
|
48.1 K | $ 0.77 | -1.68 % | $ 22.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Editas Medicine
EDIT
|
14.7 M | $ 2.15 | -2.27 % | $ 177 M | USA |
 |
Edesa Biotech
EDSA
|
19.9 K | $ 2.28 | 3.64 % | $ 7.29 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
18.4 M | $ 29.2 | -3.41 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Equillium
EQ
|
440 K | $ 1.92 | 5.49 % | $ 66.7 M | USA |